Guardant Health, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GH research report →
Range $180 – $225
Price Chart
About the company
Guardant Health, Inc. , established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI.
- CEO
- Helmy Eltoukhy
- IPO
- 2018
- Employees
- 2,498
- HQ
- Palo Alto, CA, US
Get TickerSpark's AI analysis on GH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $19.73B
- P/E
- -38.93
- Fwd P/E
- 234.77
- PEG
- 2.94
- P/S
- 15.16
- P/B
- -69.81
- EV/EBITDA
- -45.41
- Div Yield
- 0.00%
- Gross Margin
- 65.19%
- Op Margin
- -39.41%
- Net Margin
- -37.93%
- ROE
- 249.03%
- ROIC
- -32.65%
Latest fiscal year · YoY change
- Revenue
- $982.02M+32.9%
- Gross Profit
- $633.01M+40.9%
- Op Income
- $-437,248,000
- Net Income
- $-416,277,000+4.6%
- EPS
- $-3.32+6.7%
- OCF Growth
- +23.0%
- FCF Growth
- +15.2%
- 52W High
- $191.05
- 52W Low
- $74.55
- 50D MA
- $167.32
- 200D MA
- $133.44
- Beta
- 1.66
- RSI (14)
- 37
- Avg Volume
- 1.96M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Guardant Health posted broad-based third-quarter growth, lifted full-year 2026 guidance, and highlighted accelerating momentum in Shield, Guardant360, and Reveal.· November 5, 2026
- Q3 revenue rose 36% year over year to $361 million, with growth across oncology, biopharma/data, and screening.
- Oncology revenue increased 25% to $231 million; test volume rose 58% to 117,000, led by Guardant360 Liquid, Tissue, and Reveal.
- Shield revenue jumped 180% to $68 million and volume grew 246% to 83,000 tests as payer coverage and commercial execution improved.
- Management raised 2026 revenue guidance, screening outlook, and volume expectations, while keeping company-wide free cash flow breakeven by end-2027 in view.
- The company emphasized new catalysts: FDA approval for Guardant360 CDx ESR1 monitoring, a PMA filing for Guardant360 Tissue, and upcoming Smart App and Reveal Ultra launches.
Third-quarter revenue was $361 million, up 36% from $265 million a year ago. Oncology revenue was $231 million, up 25%, with oncology test volume up 58% to 117,000; biopharma and data revenue was $59 million, up 8%; and screening revenue was $68 million, up 180%, with Shield volume up 246% to 83,000 tests. Non-GAAP gross margin was 67%, up from 66% a year ago, and adjusted EBITDA loss narrowed to $37 million from $46 million in Q3 2025. Quarter-end cash and investments were $1.1 billion, and free cash flow burn improved to $37 million from $46 million. For full-year 2026, Guardant raised revenue guidance to $1.36 billion to $1.37 billion, including screening revenue of $233 million to $238 million and 285,000 to 290,000 field tests, non-GAAP gross margin of 65%, non-GAAP operating expenses of approximately $1.105 billion to $1.125 billion, and free cash flow burn of $205 million to $220 million. Oncology revenue growth is still expected at about 30% with volume growth of more than 50%, and biopharma/data remains expected to grow at a low-double-digit rate. The free cash flow outlook was raised mainly because CMS processing delays will shift $10 million to $15 million of Guardant360 Liquid CDx payments from late 2026 into early 2027; excluding that timing impact, the company said the outlook is unchanged.
Helmy Eltoukhy said the company’s platform strategy is translating into concrete clinical and commercial momentum across therapy selection, MRD, screening, and eventual multi-disease screening. He stressed that each product and approval helps move oncology toward repeated testing at key decision points rather than a one-time profile, citing the ESR1 approval, broader Smart App adoption, and Reveal therapy monitoring as examples. His tone was upbeat and strategic, with repeated emphasis that the business is still in the “early innings” of several growth drivers.
Mike Bell focused on margin expansion, cash usage, and the near-term revenue bridge. He noted non-GAAP gross margin of 67%, gross profit up $66 million year over year, operating expenses of $287 million, adjusted EBITDA loss of $37 million, and free cash flow burn of $37 million. He also highlighted Shield cost per test falling from $410 in Q2 to $330 in Q3, ahead of the year-end $350 target, and said the company remains confident in company-wide free cash flow breakeven by the end of 2027.
Analysts pressed management on Shield’s rapid adoption, ASP durability, payer contracting, and whether higher coverage and new state legislation could accelerate growth further. Management said Shield volume was above expectations because of stronger rep productivity, DTC, Quest collaboration, and ACS guideline inclusion, but cautioned that commercial contracting is still early and pricing discussions with UnitedHealthcare and others will take time. Questions on Reveal Ultra centered on clinical launch timing, Medicare coverage, and the size of the MRD opportunity; management said clinical launch is expected by year-end, studies are ramping, and they believe Reveal Ultra could be a major growth opportunity given dissatisfaction with first-generation MRD tests.
The call showed multiple growth engines working at once: oncology volume acceleration, Shield’s strong payer-driven adoption, and expanding product functionality through Smart Apps. Management also pointed to meaningful upcoming catalysts, including Guardant360 Tissue’s PMA process, Reveal Ultra’s clinical launch, and continued progress on reimbursement and coverage. The company’s full-year guidance raise and improved cash burn reinforce the message that growth is outpacing expectations while margins are holding up.
Several growth drivers still depend on execution over time, especially payer contracting, reimbursement updates, and CMS timing for Guardant360 Liquid CDx claims. Management also acknowledged that some ASP pressure could come as more under-65 commercial lives enter the mix before those payers fully reimburse. In addition, Reveal and Shield are still in the middle of validation, coverage, and launch cycles, so a lot of the upside management discussed is not yet fully reflected in reported results.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.0%
- Shares Outstanding
- 135.29M
- Float Shares
- 129.81M
of shares held by institutions
627 13F filers
Buy/sell ratio 0.85. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for GH, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Jonathan JacksonHouse · IL01 | Buy | Sep 28, 26 | Filing → |
| Sheldon WhitehouseSenate · RI | Buy | Nov 21, 25 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Feb 28, 22 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Jan 13, 22 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Dec 22, 21 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Buy | Nov 2, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Buy | Oct 22, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Buy | Oct 5, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Jul 14, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | May 1, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Sell | Apr 27, 20 | Filing → |
| Donald Sternoff BeyerHouse · VA08 | Buy | Feb 14, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 12.16M | ▲ 251.94K |
| Blackrock, Inc. | 8.00M | ▲ 379.55K |
| Fmr LLC | 7.34M | ▲ 1.85M |
| Price T Rowe Associates Inc | 6.51M | ▼ 508.74K |
| Vanguard Capital Management LLC | 5.81M | ▲ 51.80K |
| Vanguard Portfolio Management LLC | 5.34M | ▼ 110.53K |
| Goldman Sachs Group Inc | 3.78M | ▼ 659.94K |
| Two Sigma Investments, LP | 3.72M | ▼ 510.23K |
| Deep Track Capital, LP | 3.39M | ▲ 55.07K |
| Franklin Templeton Inc | 3.39M | ▲ 155.57K |
| Ameriprise Financial Inc | 3.15M | ▲ 1.74M |
| Invesco Ltd. | 2.97M | ▼ 1.46M |
Held by 670 ETFs
Biggest fund positions in GH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Monroe Terilyn J. | sell | 500 |
| Nov 18, 26 | Monroe Terilyn J. | sell | 1,200 |
| Nov 18, 26 | Monroe Terilyn J. | sell | 1,338 |
| Nov 18, 26 | Monroe Terilyn J. | sell | 704 |
| Nov 18, 26 | Monroe Terilyn J. | sell | 100 |
| Nov 17, 26 | Hidalgo Medina Manuel | other | 232 |
| Nov 17, 26 | Hidalgo Medina Manuel | other | 232 |
| Nov 16, 26 | Azar Alex M II | sell | 69 |
| Nov 15, 26 | Tariq Musa | other | 250 |
| Nov 16, 26 | Tariq Musa | sell | 116 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GH coverage
Recent articles, reports, and earnings notes.

Interpace Biosciences Uplisting: Thyroid Testing Growth Meets a Tight Float
Interpace Biosciences, Inc. (NASDAQ: IDXG) is expected to list on 2026-10-21, with a $6.00-$7.00 price range and 3.1 million shares offered. The company is already public on OTC-style markets, so this is an uplisting and offering rather than a classic first-time IPO. Bull case: a profitable thyroid diagnostics niche with growing revenue; bear case: customer concentration and reimbursement risk still matter.

Freenome, IPO: What to Know Before It Lists
Freenome, Inc. Common stock (NASDAQ: FRNM) is expected to list on 2026-07-21, but the price range has not been disclosed yet. The company is going public through a SPAC merger with Perceptive Capital Solutions Corp., not a traditional IPO. Bulls will focus on the 2026 launch plan and large healthcare-investor PIPE; bears will focus on heavy losses and a still-unproven commercialization path.

What to Watch as Cue Health Prices Its Nasdaq IPO
Cue Health Inc. (NASDAQ: HLTH) is expected to list on 2026-07-21 in a priced deal with a $15 to $17 range. The company is pitching connected diagnostics and at-home testing, but shareholders should watch how much of the story still depends on testing demand and regulatory execution.
Want a deeper read on GH?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Guardant Health Launches Guardant Reveal® Ultra to Deliver Leading Sensitivity in MRD Testing
businesswire.com · Nov 19
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Nov 13
Guardant Health Prices $500 Million Convertible Senior Notes Offering
businesswire.com · Nov 12
Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032
businesswire.com · Nov 11
Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid
businesswire.com · Nov 11
PRECISION Study Published in ESMO Open Highlights Utility of Guardant360® Liquid and Guardant Reveal® to Assess Recurrence Risk After Surgery for Colorectal Cancer Metastases
businesswire.com · Nov 10
Guardant Health to Participate in Upcoming Investor Conferences
businesswire.com · Nov 9
What Guardant Health (GH) Said on Its Q3 Earnings Call
marketbeat.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.